PF-05089771
- Generic Name
- PF-05089771
- Drug Type
- Small Molecule
- Chemical Formula
- C18H12Cl2FN5O3S2
- CAS Number
- 1235403-62-9
- Unique Ingredient Identifier
- 25U4N985O2
- Background
PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8
- Conditions
- Pain
- Interventions
- Other: Room temperatureOther: Cold temperatureDrug: Lidocain
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 36
- Registration Number
- NCT05935280
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT02349607
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, CL, Netherlands
A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
- Conditions
- Diabetic Neuropathy, Painful
- Interventions
- Drug: Matched placebo for PF-05089771 150 mg and pregabalin 300 mg
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 141
- Registration Number
- NCT02215252
- Locations
- 🇺🇸
Pulmonary Associates of Brandon (PAB), Brandon, Florida, United States
🇺🇸Beacon Clinical Research, LLC, Quincy, Massachusetts, United States
🇺🇸The Medical Research Network, LLC, New York, New York, United States
Drug-Drug Interaction Study With PF-05089771
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2014-01-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT01934569
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01854996
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
Safety And Tolerability Study Of BID Titration Scheme With PF-05089771
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2013-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT01772264
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT01769274
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study Comparing PF-05089771 TS Capsule To PF-05089771 TS Oral Dispersion In The Fasted State
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01690351
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Study Comparing PF-05089771 TS Tablet to PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And Fed State
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01563497
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT01529671
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.